VTRS

시간 외 거래: 15.82 -0.13 -0.82%

비아트리스 (VTRS)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할 배당 이력

Relative Volume:

비아트리스 Stock (VTRS) Company Profile

Healthcare (1111)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

최신 SEC 제출 서류

VTRS's Discussions on Twitter

Compare VTRS vs TAK, ZTS, TEVA, HLN, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
VTRS Viatris Inc	15.95	18.07B	14.29B	-3.51B	1.85B	-2.9603
TAK Takeda Pharmaceutical Co Adr	16.72	52.28B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	111.22	47.33B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	36.34	41.76B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.23	40.70B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	596.76	24.28B	3.18B	1.33B	1.04B	27.90

비아트리스 Stock (VTRS) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-02-09	업그레이드	UBS	Neutral → Buy
2026-01-16	업그레이드	Argus	Hold → Buy
2025-12-09	개시	Barclays	Overweight
2025-10-15	개시	Truist	Buy
2025-06-06	개시	Goldman	Neutral
2024-07-19	재개	Jefferies	Buy
2023-10-23	다운그레이드	BofA Securities	Neutral → Underperform
2023-06-23	다운그레이드	Barclays	Equal Weight → Underweight
2023-04-24	다운그레이드	Barclays	Overweight → Equal Weight
2023-02-17	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2023-01-27	업그레이드	Jefferies	Hold → Buy
2022-11-10	업그레이드	UBS	Sell → Neutral
2022-11-08	업그레이드	Piper Sandler	Underweight → Neutral
2022-10-21	재개	Jefferies	Hold
2022-06-14	개시	UBS	Sell
2022-05-10	다운그레이드	Piper Sandler	Neutral → Underweight
2022-03-01	다운그레이드	BofA Securities	Buy → Neutral
2022-03-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2021-06-15	개시	Citigroup	Neutral
2021-04-07	재개	RBC Capital Mkts	Outperform
2021-03-08	다운그레이드	Goldman	Buy → Neutral
2021-03-02	다운그레이드	JP Morgan	Overweight → Neutral
2021-02-26	다운그레이드	Wolfe Research	Outperform → Peer Perform
2021-01-05	개시	Argus	Hold
2020-12-14	개시	Bernstein	Mkt Perform

비아트리스 주식(VTRS)의 최신 뉴스

비아트리스 (VTRS) 재무 분석

비아트리스 (VTRS)

비아트리스 Stock (VTRS) Company Profile

Compare VTRS vs TAK, ZTS, TEVA, HLN, UTHR

비아트리스 Stock (VTRS) Upgrades & Downgrades

비아트리스 주식(VTRS)의 최신 뉴스

Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch

Investors brace for Viatris earnings as CFO departure looms By Investing.com - Investing.com

Viatris Q1 2026 Earnings Preview: Caution remains around ongoing turnaround (VTRS:NASDAQ) - Seeking Alpha

Viatris CFO leaving Canonsburg pharma giant - WPXI

Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS - Yahoo Finance

Are Wall Street Analysts Bullish on Viatris Stock? - Barchart.com

Viatris To Go Ex-Dividend On May 22nd, 2026 With 0.12 USD Dividend Per Share - Moomoo

Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch

Viatris Gears Up to Report Q1 Earnings: What's in the Cards? - Yahoo Finance

Viatris Names Paul Campbell Interim CFO as Doretta Mistras Announces Departure - citybiz

Maryland reaches $4.5 million settlement with EpiPen makers - Baltimore Sun

Edwards names Theodora Mistras as CFO - MedTech Dive

Davis Selected Advisers (NASDAQ: VTRS) reports 78.21M shares, 6.8% stake - Stock Titan

MSN Money - MSN

Avoiding Lag: Real-Time Signals in (VTRS) Movement - Stock Traders Daily

Viatris declares $0.12 quarterly dividend per share - Investing.com

Viatris declares $0.12 quarterly dividend per share By Investing.com - Investing.com Canada

Viatris sets June 17 payment for $0.12 a share quarterly dividend - Stock Titan

Viatris Announces Quarterly Dividend - ChartMill

Viatris Announces CFO Transition: Theodora Mistras Departs, Paul Campbell Appointed Interim CFO - Minichart

Viatris declares $0.12 quarterly dividend payable June 17, 2026. - Pluang

Viatris CFO to depart; interim CFO named - MSN

Viatris Names Paul Campbell Interim Chief Financial Officer - TipRanks

Viatris Announces Chief Financial Officer Transition - The Malaysian Reserve

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

Viatris CFO Doretta Mistras to leave, Paul Campbell named interim By Investing.com - Investing.com Australia

Edwards Lifesciences Announces Appointment of CFO - Business Wire

Viatris (Nasdaq: VTRS) appoints Paul Campbell as interim CFO - Stock Titan

Viatris announces chief financial officer transition - marketscreener.com

Earnings Preview: Viatris to Report Financial Results Pre-market on May 07 - Moomoo

Viatris Contraceptive Patch Data Puts Women’s Health Growth Story In Focus - Sahm

Is It Too Late To Consider Viatris (VTRS) After Its Strong One Year Share Price Run - Yahoo Finance

Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune

VTRS SEC FilingsViatris Inc Ord Shs 10-K, 10-Q, 8-K Forms - Stock Titan

Viatris presents data on low-dose contraceptive patch at ACOG By Investing.com - Investing.com India

Viatris presents data on low-dose contraceptive patch at ACOG - Investing.com

Weekly birth control patch data gets 6 slots at major OB-GYN meeting - Stock Titan

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting - ChartMill

Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30? - Insider Monkey

Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS) - Stock Titan

Merz Gets 2 More Months To Block Generic MS Drug - Law360

Viatris (VTRS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Viatris Inc Profile: Summary - OpenSecrets

Trazodone Market Growth Size 2026, Trends, Industry Analysis, - openPR.com

Viatris Inc. (VTRS) Stock Analysis: Exploring Potential Gains With A 7.76% Upside - DirectorsTalk Interviews

Does Xanax XR Recall Over Dissolution Issues Change The Bull Case For Viatris (VTRS)? - simplywall.st

Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN

Viatris shares break six-session winning streak - MSN

Viatris Inc. stock rises Friday, outperforms market - MSN

VTRS Price Today: Viatris Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Viatris Inc. stock falls Friday, underperforms market - MarketWatch

비아트리스 (VTRS) 재무 분석

매출

순이익

현금흐름

주당 순 이익

VTRS과 유사한 종목